Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GMTX Stock Forecast 2026-2027
$60.04
Current Price
$0
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to GMTX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
GMTX Price Momentum
-1.9%
1 Week Change
+7.3%
1 Month Change
+17.7%
1 Year Change
-24.4%
Year-to-Date Change
-39.7%
From 52W High of $99.50
+94.8%
From 52W Low of $30.82
📊 TOP ANALYST CALLS
Did GMTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Gemini Therapeutics is one of their latest high-conviction picks.
Latest GMTX Stock Price Targets & Analyst Predictions
GMTX has shown a year-to-date change of -24.4% and a 1-year change of 17.7%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for GMTX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GMTX Analyst Ratings
0
Buy
0
Hold
0
Sell
GMTX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $60.04
Latest GMTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GMTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2022 | HC Wainwright & Co. | Andrew Fein | Neutral | Downgrade | $2.00 |
| Mar 3, 2022 | SVB Leerink | Marc Goodman | Market Perform | Downgrade | $2.00 |
| Mar 1, 2022 | Jefferies | Chris Howerton | Hold | Downgrade | $1.50 |
| Jan 24, 2022 | SVB Leerink | Outperform | Maintains | $10.00 | |
| Dec 20, 2021 | SVB Leerink | Marc Goodman | Outperform | Maintains | $15.00 |
| Dec 15, 2021 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Oct 6, 2021 | Goldman Sachs | Graig Suvannavejh | Buy | Maintains | $18.00 |
| Apr 8, 2021 | SVB Leerink | Outperform | Initiates | $N/A | |
| Mar 3, 2021 | Jefferies | Buy | Initiates | $N/A | |
| Mar 2, 2021 | Goldman Sachs | Buy | Initiates | $N/A |
Gemini Therapeutics, Inc. (GMTX) Competitors
The following stocks are similar to Gemini Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GMTX
Gemini Therapeutics
mkt cap
478.04M
Gemini Therapeutics, Inc. (GMTX) Financial Data
Valuation Metrics
Market Cap
$0
Enterprise Value
$-131,223,000
P/E Ratio
-13.4x
PEG Ratio
N/A
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
N/A
Current Ratio
91.9x
Debt/Equity
0.0x
ROE
+38.9%
ROA
-51.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Gemini Therapeutics, Inc. (GMTX) Business Model
About Gemini Therapeutics, Inc.
What They Do
N/A
Business Model
N/A
Additional Information
N/A
Company Information
Sector
Industry
Employees
0
CEO
Country
United States
IPO Year
2020
Website
www.geminitherapeutics.comGemini Therapeutics, Inc. (GMTX) Latest News & Analysis
Latest News
Quick Summary
The FDA has denied or discouraged applications for at least eight new drugs in the past year, including initially refusing to review Moderna's flu shot before later reversing its decision.
Why It Matters
The FDA's increasing scrutiny on new drug applications signals potential delays in product launches, impacting revenue forecasts for pharmaceutical companies like Moderna.
Source: CNBC
Market Sentiment:
Negative
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation
3 years ago
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for FS Development Corp. investors post-merger with Gemini Therapeutics (NASDAQ: GMTX) on February 5, 2021.
Why It Matters
Potential legal claims against FS Development Corp. post-merger with Gemini Therapeutics may indicate financial or operational issues, impacting stock performance and investor confidence in GMTX.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Disc Medicine, Inc. received FDA Orphan Drug Designation for bitopertin to treat erythropoietic protoporphyria, advancing its development in hematologic diseases.
Why It Matters
Orphan Drug Designation can expedite bitopertin's development and approval for EPP, potentially leading to market exclusivity and increased investor confidence in Disc Medicine's pipeline.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Short-squeeze stocks have gained popularity as investors bet against bearish traders, creating a high-stakes trading environment.
Why It Matters
The rise of short-squeeze stocks indicates increased volatility and trading opportunities, potentially affecting stock prices and investor strategies in the market.
Source: InvestorPlace
Market Sentiment:
Positive
Quick Summary
Disc Medicine has initiated the Phase 2 AURORA study to evaluate bitopertin for treating adults with EPP. Results on safety and efficacy are expected in 2023.
Why It Matters
The AURORA study's results could significantly impact Disc Medicine's stock by influencing its market position and potential revenue from a new treatment for EPP.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating Gemini Therapeutics (NASDAQ: GMTX) for potential securities law violations related to its merger with Disc Medicine, where pre-merger shareholders will hold 28% of the new entity.
Why It Matters
Potential legal scrutiny into Gemini Therapeutics' merger could impact stock performance and shareholder value, influencing investor confidence and trading decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About GMTX Stock
What is Gemini Therapeutics, Inc.'s (GMTX) stock forecast for 2026?
Analyst forecasts for Gemini Therapeutics, Inc. (GMTX) are not currently available. The stock is trading at $60.04.
Is GMTX stock a good investment in 2026?
Analyst ratings for GMTX are not currently available. The stock is currently trading at $60.04. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GMTX stock?
Price predictions from Wall Street analysts for GMTX are not currently available. The stock is trading at $60.04.
What is Gemini Therapeutics, Inc.'s business model?
N/A
What is the highest forecasted price for GMTX Gemini Therapeutics, Inc.?
Price targets from Wall Street analysts for GMTX are not currently available. The stock is trading at $60.04.
What is the lowest forecasted price for GMTX Gemini Therapeutics, Inc.?
Price targets from Wall Street analysts for GMTX are not currently available. The stock is trading at $60.04.
What is the overall GMTX consensus from analysts for Gemini Therapeutics, Inc.?
Analyst ratings for GMTX are not currently available. The stock is trading at $60.04.
How accurate are GMTX stock price projections?
Stock price projections, including those for Gemini Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 9:14 PM UTC